X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Concentra will get access to THE-349, which is a small molecule designed to inhibit all major classes of EGFR activating and resistance mutations being evaluated for the treatment of non-small cell lung cancer.
Lead Product(s): THE-349
Therapeutic Area: Oncology Product Name: THE-349
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Concentra Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 14, 2024
Details:
Through th acquisition, Concentra expand its portfolio by gaining Theseus' pipeline, including THE-349, a fourth-generation, selective epidermal growth factor receptor inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment of NSCLC.
Lead Product(s): THE-349
Therapeutic Area: Oncology Product Name: THE-349
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Concentra Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 21, 2023
Details:
THE-630 is a pan-variant tyrosine kinase inhibitor (TKI) of the receptor tyrosine kinase KIT, designed for patients with GIST that have developed resistance to earlier lines of therapy.
Lead Product(s): THE-630
Therapeutic Area: Oncology Product Name: THE-630
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
THE-630 is a pan-variant tyrosine kinase inhibitor (TKI) of the receptor tyrosine kinase KIT, designed for patients with GIST that have developed resistance to earlier lines of therapy.
Lead Product(s): THE-630
Therapeutic Area: Oncology Product Name: THE-630
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Theseus pharmaceutical introduced its third development program, a pan-variant tyrosine kinase inhibitor (TKI) targeting BCR-ABL for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
THE-349 demonstrates brain-penetrability and exhibits substantial CNS activity, which is necessary to address the relatively common recurrence of NSCLC in the brain.
Lead Product(s): THE-349
Therapeutic Area: Oncology Product Name: THE-349
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
THE-349 is fourth-generation, potent and selective, small molecule designed to address treatment resistance to existing EGFR inhibitors by targeting common activating mutations in exons 19 and 21 alone or in combination with the most frequently observed resistance mutations.
Lead Product(s): THE-349
Therapeutic Area: Oncology Product Name: THE-349
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
The preclinical data presented at AACR demonstrates that pan-variant EGFR inhibition of all major single-, double-, and triple-mutants, including T790M and C797S, with selectivity over wild-type, is achievable with a single molecule.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Under the agreement, Vipergen will apply its in-living-cell DNA-encoded library screening platform to discover novel small-molecule that binds to a selected Theseus kinase target. Theseus will select hits for potential development into targeted tyrosine kinase inhibitors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Vipergen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 04, 2022
Details:
The presentation will detail the characterization of compounds that inhibit the kinase activity, both in vitro and in vivo, of single, double, and triple mutant EGFR variants including T790M and C797S, with selectivity over wild-type EGFR and the ability to penetrate CNS.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
